GLI1 and diabetic kidney disease: To further elucidate the role of GLI1 in GABP‐mediated renal fibrosis in a murine model of diabetic nephropathy, we administered the GLI1 inhibitor GANT61 subcutaneously at a dosage of 30 mg kg−1 to both db/m‐OE and db/db mice (Figure 8A,H).